Write a commentEpidemiologist Nicholas Hulscher reported that in the largest study of Ivermectin and Mebendazole anti-parasitic treatments, nearly half of the patients in the study reported a disappearance of the cancer or tumor regression. He wrote that 32.8% of the study participants showed no more evidence of disease after 6 months, 15.6% reported tumor regression and 36.1% reported that the disease had stabilized and was no longer spreading.
The clinical program evaluation included 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).
The cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.
NOTE: The Need To Know News does not endorse any medical treatments, but instead reports the news. Please consult your own medical health experts before engaging in any medical treatments.